Lumosa Therapeutics Co., Ltd. (Lumosa) and AMed Co., Ltd. (AMed) originally signed an agreement on June 8th, 2018, for the licensing rights of LT1001, an extended-release analgesic injection (Product), in Southeast Asian market. The total license fee was up to TWD 250 million, including an upfront payment of TWD 10 million as well as milestone payments, and royalty from the sales of the product. AMed received the exclusive rights to submit drug registration, technological licensing, market development and sales for the Product in Indonesia, Malaysia, Philippines, Thailand, Singapore, Brunei, Cambodia, Laos, Myanmar, and Vietnam.

The amount for milestone payments and royalties depend on the execution of drug registration and sales performance of the Product. To accelerate marketing progress of the Product, additional milestones are installed. Payments are subject to market approval and the sales performance of the Product in each country.

The total licensing fee is adjusted to TWD 253.6 million while all other terms remain unchanged.